Please login to the form below

Not currently logged in
Email:
Password:

Tesaro

This page shows the latest Tesaro news and features for those working in and with pharma, biotech and healthcare.

China’s BeiGene raises $903m from Hong Kong IPO

China’s BeiGene raises $903m from Hong Kong IPO

It’s a potential rival to marketed PARP inhibitors from AstraZeneca (Lynparza), Clovis Oncology (Rubraca) and Tesaro (Zejula).

Latest news

More from news
Approximately 8 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Licence. 339. TeneoBio/TESARO. Multi-specific antibodies for up to six undisclosed oncology targets using UniRat® platform and discovery engine TeneoSeek.

  • Deal Watch February 2017 Deal Watch February 2017

    There has been speculation for several months that oncology company Tesaro may be the target for a large pharma bid and as a result its share price has increased by 570%

  • Deal Watch April 2016 Deal Watch April 2016

    Apart from the 3 deals by Abbvie, there were deals by GSK and Janssen with Zymeworks and Tesaro respectively. ... 500. Tesaro (US). Janssen (US). License and collaboration. Niraparib PARP inhibitor in clinical phase for treatment of prostate cancer.

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    350.5. AnaptysBio/ Tesaro. Collaboration, licence. mAbs to activate immune system response "checkpoints" - 3 targets: TIM-3, LAG-3 and PD-1 (preclinical).

  • Pharma deals during March 2014 Pharma deals during March 2014

    The second deal, the $341m discovery transaction between AnaptysBio and Tesaro, is focused on the development of antibodies that activate immune checkpoints disabled by various cancers.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics